1 is the major biologically active form of vitamin A. This vitamin is important for normal growth and development, especially during embryogenesis where a three-dimensional gradient of RA determines pattern formation (1) . It is also an important regulator of reproduction (2) , differentiation (3) , and apoptosis (4) . Additionally, RA has been found to inhibit the growth of malignant cells (5, 6) and/or to induce reversion from the malignant to the normal phenotype (7) . Most, if not all, of all these effects are mediated though retinoid nuclear receptors. There are two families of retinoid nuclear receptors: RARs and RXRs. Each family of nuclear retinoic acid receptors consists of ␣, ␤, and ␥ subtypes (8 -10) . These nuclear receptors are ligand-dependent transcriptional regulators, with RXR being activated by 9-cis-RA, whereas RAR are activated by either all-trans-RA or 9-cis-RA (11) (12) (13) . RXR can form homodimers with a number of other type II nuclear receptors, including RAR (14, 15) . In contrast, RAR only forms heterodimers with RXR (16) . Following ligand binding, RXR⅐RAR heterodimers bind to the promoter of target genes and stimulate their transcription (17) . In B16 mouse melanoma cells RAR␣ and RAR ␥ are constitutively expressed, whereas RAR␣ expression can be induced by incubation of cells with RA (18) .
Nuclear retinoic acid receptors are phosphoproteins. RAR␣ is phosphorylated in vivo by cyclic AMP-dependent protein kinase (PKA) (19) and cyclin-activating kinase (CAK) (20) . Phosphorylation of RAR␣ by PKA in F9 cells is required for RAinduced parietal endoderm differentiation (21) . In contrast, proline-directed phosphorylation sites (such as those phosphorylated by CAK) in RAR␥ were required for RA induction of primitive endoderm differentiation (22) . The PKA phosphorylation site in RAR␥ was dispensable for this biological activity of RA (21) .
Protein kinase C (PKC) is a serine/threonine protein kinase and plays a role in the regulation of growth, differentiation, and other cellular functions (23) . The PKC family includes at least 11 different enzymes that are classified into three families based on requirement for phospholipids, diacylglycerol, or Ca 2ϩ for their activation (24, 25) . Following activation, PKC is translocated to different cellular compartments where it phosphorylates substrate proteins. In addition, PKC has been shown to transverse the nuclear membrane and phosphorylate targets in the nucleus (26) . The transcription complex activating protein 1 is activated by PKC (27) , which provides a means for PKC to influence gene expression.
It has been proposed that there is an interaction between PKC and retinoic acid receptors. PKC has been shown to phosphorylate RAR in vitro (28, 29) . On the other hand, one group has reported that RA binds to PKC in a specific manner and inactivates its enzymatic activity (30) . We have previously reported that treatment of B16 melanoma cells with RA increases the amount of PKC␣ mRNA and protein (31) . In light of the purported interaction between PKC and RAR, we investigated whether the increased amount of PKC␣ in B16 cells might phosphorylate the RAR and alter its function. We found, in B16 mouse melanoma cells, that RAR␣ is not a target for PKCdirected phosphorylation. However, we discovered that activation of PKC in these cells resulted in an increase in RAR␣ protein. The increase in RAR␣ was due to an increase in the half-life of this protein, which correlated with an increase in AF-2 activity. In contrast, down-regulation of PKC through prolonged phorbol dibutyrate (PDB) treatment led to a large decrease in AF-2 activity, which cannot be totally accounted for by diminished RAR stability. Our studies suggest that there exists a significant cross-talk between the PKC and RAR signal transduction pathways.
EXPERIMENTAL PROCEDURES
Cell Culture-B16 mouse melanoma cells were grown in DMEM (Invitrogen, Rockville, MD) supplemented with 10% bovine calf serum (HyClone Laboratories, Logan, UT) at 37°C, in a 5% CO 2 /95% air, humidified atmosphere. Cells were treated for the periods described in each experiment with 10 M phorbol 12,13-dibutyrate (PDB) (Sigma Chemical Co., St. Louis, MO) or 10 M all-trans-RA (Fluka Chemical Corp., Ronkonkoma, NY). All manipulations involving RA were conducted under subdued lighting or yellow light to prevent photo-oxidation.
Cloning of mRAR␣ into a Histidine-tagged Expression Vector-A mRAR␣ cDNA fragment encoding the complete open reading frame, except for the last three C-terminal amino acids was produced by PCR using the following primers: 5Ј-GGACTGGCCAGCAACAGC-3Ј (upstream primer) and 5Ј-GGCCGGGCTGCTTCTGTT-3Ј (downstream primer) using the Advantage cDNA PCR kit (CLONTECH, Palo Alto, CA). The template for this reaction was mRAR␣ in pSG5 that was kindly provided by Dr. Pierre Chambon (Institut de Genetique et de Biologie Moleculaire et Celluaire, CNRS/INSERM, Strasbourg, France). PCR was conducted by incubating at 94°C for 1 min followed by 20 cycles at 94°C for 30 s and 68°C for 3 min, and ending with incubation at 68°C for 3 min. Following authentication of the PCR product by DNA sequencing, it was cloned into the pcDNA3.1/V5/ His-TOPO plasmid (Invitrogen, Carlsbad, CA) producing RAR␣-His. In vitro transcription/translation of this construct resulted in a protein that was about 5 kDa larger than wild type RAR␣. Histidine-tagged RAR␣ had the same ligand binding and DNA binding properties as wild type RAR␣ (data not shown).
Kinase-inactive PKC␣ Constructs-Two plasmids expressing enzymatically inactive PKC␣ were gifts from Dr. S. Ohno, Yokohama City University School of Medicine, Japan. One of these constructs (PKC␣-Kn-SM) has a single K368R mutation in the ATP binding region. The other construct (PKC␣-Kn-TM) has the same K368R mutation in addition to two amino acid mutations (R22A and A25E) in the pseudosubstrate region. Both PKC␣ mutants expressed from these constructs have no kinase activity. PKC␣-Kn-SM is thought to be in a "closed" conformation, because it lacks the ability to autophosphorylate to achieve the mature conformation. PKC-Kn-TM, in contrast, is thought to have an "open" conformation due to the mutation in the pseudosubstrate region. B16 clones expressing these mutant PKC␣ proteins were used to examine the requirement of PKC enzyme activity for its effect on RAR stability.
Transient Transfections-RAR␣-His, pSG5 RAR␣, ␤, or ␥ (gifts from Dr. Chambon), RARE-tk-luciferase (gift from Dr. Ozato, Laboratory of Molecular Growth Regulation, National Institutes of Health, Bethesda, MD), and pSV-␤-gal plasmids were transiently transfected into B16 cells using LipofectAMINE Plus (Invitrogen, Rockville, MD) according to the manufacturer's recommended protocol. For reporter gene assays, transfected cells were treated with PDB and/or RA for the indicated times, and 48 h after transfection cells were harvested and assayed for luciferase or ␤-galactosidase activity using kits from Promega (Madison, WI).
Western Blotting-Cells were lysed in buffer A (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 10% glycerol, 1 g/ml leupeptin, 1 g/ml pepstatin, 2 g/ml aprotinin, and 3.28 g/ml PMSF) by three consecutive 10-s sonications with a Tekmar sonic disrupter at power setting 60. Proteins were separated by SDS-PAGE (5% stacking gel; 10% separating gel) and transferred to nitrocellulose (Micron Separation, Inc., Westborough, MA) using a semi-dry blotting apparatus (Bio-Rad, Hercules, CA). The membranes were incubated with 10% nonfat dry milk overnight at room temperature. The membrane was then washed 3ϫ with TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 5 min each, at room temperature and then probed with a 1:5000 dilution of anti-V5 monoclonal antibody (Invitrogen, Carlsbad, CA) for 1 h at room temperature. Subsequently, the membrane was washed as described above and further incubated with horseradish peroxidase-conjugated sheep anti-mouse IgG (Amersham Biosciences, Piscataway, NJ) at room temperature for 1 h. The membrane was washed three times with TBST and developed using the ECL chemiluminescence kit (Amersham Biosciences). Intensity of the RAR␣-His immunoreactive bands was quantified using a Molecular Dynamics densitometer (Sunnyvale, CA).
-Phosphatase MO) . At the end of this incubation, cells were washed and harvested in cold PBS. RAR␣ was purified by immunoprecipitation as described below and separated by SDS-PAGE on a 7.5% gel. The gel was dried and then exposed to x-ray film for 72 h.
Immunoprecipitation and Determination of RAR␣-His Protein Halflife-B16 cells were transfected with the RAR␣-His construct as described previously. At 44 h post-transfection, media was removed and replaced with methionine-free DMEM (Invitrogen, Rockville, MD) for 1 h. This medium was then replace with fresh methionine-free medium to which 100 Ci/ml [ 35 S]methionine (PerkinElmer Life Sciences, Boston, MA) was added, and the cells were incubated for an additional 2 h. At different times of experimental treatment, medium was removed and cells were washed with PBS and harvested in 0.9 ml of radioimmune precipitation buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 1% SDS, 100 g/ml PMSF, 30 g of aprotinin, 1 mM sodium orthovanadate in PBS). Cells were disrupted by repeated aspiration through a 21-gauge needle. The cell lysate was centrifuged at 10,000 ϫ g for 10 min at 4°C, and the supernatant was precleared by the addition of 1 g of mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) together with 20 l of protein A-agarose (Santa Cruz Biotechnology) for 30 min at 4°C. The protein A-agarose was removed by centrifugation at 2500 ϫ g for 5 min at 4°C, 0.7 g of anti-V5 epitope antibody was then added, and the mixture was incubated for 1 h at 4°C. Immune complexes were collected by the addition of 20 l of protein A-agarose for 1 h at 4°C followed by centrifugation at 2500 ϫ g for 5 min at 4°C. The immunoprecipitate was washed three times by resuspension in 1 ml of radioimmune precipitation buffer followed by centrifugation as described previously. The pellet was resuspended in 30 l of SDS samples buffer, and 25 l was loaded onto a 5% stacking/10% separating SDS gel for protein separation by electrophoresis. The gel was then dried using a Model 583 gel drier (Bio-Rad, Hercules, CA), and the RAR␣-His protein was detected by autoradiography. The amount of RAR␣-His was determined by densitometry.
Northern Blotting-RNA was isolated by a single-step method as described previously (32) . The RNA was then fractionated on 1% agarose containing formaldehyde and transferred to Hybond N nylon membranes (Amersham Biosciences, Chicago, IL) by downward alkaline blotting. The transferred RNA was cross-linked to the membrane by UV light. The membrane was prehybridized for 1 h in 6ϫ SSC and 2% SDS. 32 P-Labeled cDNA probes (1 ϫ 10 6 dpm/ml) were then incubated with the membranes in fresh hybridization solution for 20 h. Blots were washed three times for 15 min each in 1ϫ SSC plus 0.1% SDS, 0.5ϫ SSC plus 0.1% SDS, and 0.2ϫ SSC plus 0.1% SDS, respectively. The blots were exposed to Kodak XAR film in cassettes at Ϫ70°C for 2-5 days. All the cDNA probes were labeled using the "prime-a-gene" labeling system from Promega (Madison, WI) plus 0.25 mCi of [␣-
32 P]dCTP. The relative amount of the different RNA species was quantitated by imaging the autoradiogram with a Molecular Dynamics laser densitometer, making sure that the signals were within the linear range of the instrument. The data are expressed as the ratio of the specific mRNA to the internal control, glyceraldehyde-3-phosphate dehydrogenase.
Electrophoretic Mobility Shift Assay-Two 33-bp DNA oligonucleotides were annealed to form a double-stranded oligonucleotide, which contained a retinoic acid response element corresponding to that found within the human RAR␤ gene promoter (33) . This ␤RARE was labeled with [␣-32 P]dCTP (3000 Ci/mmol) by end-filling of the 5Ј-protruding termini with the Klenow fragment of DNA polymerase I. The labeled ␤RARE was purified using a Qiagen Tip-20, precipitated with 10 mg of glycogen carrier in ethanol:acetone (1:3, v/v) at Ϫ80°C, and resuspended in double distilled H 2 O.
Gel shift reactions typically contained B16 nuclear extract (25 g) or Sf9 cell extracts from recombinant hRAR␣1 baculovirus-infected cells (1 g), 10% (v/v) glycerol, 10ϫ reaction buffer (0.2 M HEPES, pH 7.9, 0.6 M KCl, 0.01 M Na 2 EDTA, 0.1 M monothioglycerol, and 0.01 M PMSF), 2.5 g of poly(dI-dC), and 2 ϫ 10 4 cpm of [␣- 32 P]␤RARE in a 20-ml total volume. The reactions were incubated for 20 min at 23-24°C and immediately resolved at 20 mA at 23°C in a 5% non-denaturing gel (60:1, acrylamide:bis) in 0.5ϫ TBE (0.045 M Tris borate, pH 8.0, 0.001 M Na 2 EDTA). Dried gels were exposed to film between intensifying screens at Ϫ80°C.
All experiments described under "Results" were repeated three separate times with similar qualitative results.
RESULTS

RAR␣ Ectopically Expressed in B16 Melanoma
Cells Is Phosphorylated-Expression of endogenous RAR in B16 cells is very low and below the detection limit of Western blotting/immunoprecipitation techniques. Thus, for the studies reported here, we used recombinant histidine-tagged RAR␣ transiently transfected and expressed in B16 cells. Histidine-tagged RAR␣ protein had the same ligand binding and DNA binding properties as wild type RAR␣ (data not shown). Expression of the recombinant RAR␣ was confirmed by Western blotting, using an antibody directed against the histidine tag or an antibody to the V5 epitope, which is also part of the tagged protein. Three immunoreactive RAR␣ bands were most often observed in extracts of transfected B16 cells, corresponding to 50 -54 kDa. When these extracts were treated with -protein phosphatase for different periods of time, the two RAR␣ bands of higher molecular mass collapsed into the lowest molecular mass band ( Fig. 1) indicating that the His 6 -RAR␣ protein is phosphorylated in B16 cells. Elsewhere, in data presented, multiple bands of RAR␣ may not be apparent. This is due to different gel running conditions and signal detection conditions required to display these multiple bands.
Activation and Down-regulation of PKC Does Not Alter the Phosphorylation of RAR␣ in B16 Mouse Melanoma Cells-We
have previously shown that incubation of B16 cells with phorbol dibutyrate for 1 or 24 h activates or down-regulates PKC␣, respectively (34) . Therefore, we used these phorbol dibutyrate treatment times to determine whether activation/down-regulation of PKC altered the phosphorylation of RAR␣. Fig. 2A shows that treatment of B16 cells with phorbol dibutyrate did not change the number of the RAR␣-immunoreactive bands (although the amount of RAR␣ protein was higher in the 1-h phorbol dibutyrate-treated cells, see below). Also, the ratio of the relative amount of the different bands within each treatment group was not altered. In addition, radioactive labeling of intact cells with 32 P i -orthophosphate did not reveal any change in the amount of incorporation of the label into His 6 -RAR␣ in short or long term phorbol dibutyrate-treated cells when the signals were corrected for amount of receptor protein (Fig. 2B) .
Increase in PKC Activity Results in Higher RAR␣ Protein Levels in B16 Cells-Even though changes in PKC activity/ expression did not alter the phosphorylation of RAR␣, an increase in PKC activity did result in a consistent 2-fold elevation in RAR␣ protein levels ( Fig. 2A) . In contrast, down-regulation of PKC activity did not markedly change the level of RAR␣ protein when compared with the control.
To explore this phorbol dibutyrate-induced change in RAR␣ protein in more detail, B16 cells were incubated with phorbol dibutyrate for different periods of time and the amount of RAR␣ protein was determined by Western blotting. A delay of 30 min was observed before a change in RAR␣ protein levels could be detected. RAR␣ protein levels reached a maximum, of about 3-fold over the control level, at 10 h following phorbol dibutyrate addition (Fig. 3A) . Subsequently, RAR␣ protein levels declined and reached control levels 24 h following addition of phorbol dibutyrate. These levels remained unchanged for the RAR␣ was then isolated by immunoprecipitation and separated on 7.5% SDS gels. The radioactive bands were detected by autoradiography, and the relative amount of phosphorylated RAR␣ (B) was determined by densitometry of both the autoradiogram and silver-stained gels for estimates of total RAR␣ protein (insets). The data are presented as the mean relative level of phosphorylation, corrected for the amount of total RAR␣ of three separate experiments. The error bars represent the S.E. of the three experiments.
remainder of the 72-h treatment period. The change in RAR␣ protein level as a function of phorbol dibutyrate concentration was also analyzed. A concentration of 0.1 M phorbol dibutyrate was able to increase RAR␣ protein levels by 2-fold following a 1-h treatment (Fig. 3C) PKC Activity Is Required for the Increase in RAR␣ Protein Levels in B16 Cells-We investigated whether PKC enzyme activity was required for the observed increase in RAR␣ protein by using both a chemical enzyme inhibitor and dominant-negative mutants of PKC␣, which lack enzymatic activity. Bisindolylmaleimide, a selective PKC enzyme inhibitor, completely abolished the phorbol dibutyrate-induced increase in RAR␣ protein (Fig. 4A) . Clones of B16 cells stably expressing two different types of PKC␣ dominant-negative mutants were tested for the ability of phorbol dibutyrate to increase the amount of ectopically expressed RAR␣. Both of these clones have markedly less PKC-specific enzyme activity than wild type B16 cells (Table I) . Short or long term phorbol dibutyrate treatment was not able to significantly change RAR␣ protein levels in these clones of B16 cells further demonstrating the requirement for PKC enzyme activity to increase the amount of RAR␣ protein (Fig. 4B) .
PKC Regulates Stability of the RAR␣ Protein in B16 Cells-
The PKC enzyme-dependent increase in RAR␣ protein could be the result of either increased mRNA or increased stability of the protein. Because we observed the increase in RAR␣ protein within 1 h of addition of PDB to the cells, we considered an effect at the RNA level unlikely, thus we examined the effect of PKC activation on the stability of RAR␣ protein. The half-life of ectopically expressed RAR␣ in B16 cells was determined to be 4 h. When B16 cells were treated with PDB for 1 h, the RAR␣ protein half-life increased to somewhat greater than 8 h (Fig.  5) . In contrast, when PKC was down-regulated by a 24-h treatment with phorbol dibutyrate, the half-life of RAR␣ decreased slightly to ϳ3 h (Fig. 5) .
Altering PKC Activity Changes the Transcriptional Activation Function of the RAR-To further study the effect of PKC on RARs, RAR-dependent transcriptional activity was measured in an RARE reporter assay using thymidine kinase promoter/luciferase reporter plasmid. In response to PKC activation RAR-dependent transcriptional activity was increased ϳ2.8-fold when compared with the control (untreated) cells. On the other hand, down-regulation of PKC resulted in a 2-fold decrease in the transcriptional activity (Fig. 6A) . Similar effects were observed with ectopically expressed RARs (Fig. 6B) . One-hour PDB treatment resulted in an increase in RA-stimulated reporter gene activity in all of the RARs. In contrast, the down-regulation of PKC resulted in a large reduction of RAstimulated reporter gene activity in all of the ectopically expressed RARs.
Lower RAR-dependent Transcriptional Activity Is a Result of the Less RAR Being Bound to the DNA-A gel shift assay was conducted using nuclear extracts from the cells treated with phorbol dibutyrate for 1 and 24 h. The cells were also treated with 10 M RA for 24 h. The DNA⅐protein complex contains RARs, because it was possible to supershift the complex using the RAR antibody. Pre-treatment of the cells with RA increased the amount of the shifted complex (lane 3, Fig. 7 ). When nuclear extracts from B16 cells treated for 24 h with phorbol dibutyrate were used in gel shift assays, a decrease in the amount of the shifted complex was observed (lane 5 versus lane 2, Fig. 7) . A small increase in the amount of RAR bound to DNA was observed with nuclear extracts from cells in which PKC activity was elevated (lane 4, Fig. 7) .
PKC Down-regulation Inhibits the Retinoic Acid Induction of RAR␣ mRNA in the B16 Mouse Melanoma Cells-RAR␣ is not expressed under normal conditions in B16 mouse melanoma cells. However, it contains a retinoic acid response element (RARE), and therefore its expression can be induced by incubation with retinoic acid. Treatment of B16 cells with 10 M RA for 4 h results in a 20-to 25-fold induction in RAR␣ mRNA (18) . When PKC activity in B16 cells was manipulated by short and long term phorbol ester treatment, it was observed that long term treatment, which down-regulates PKC activity, inhibited the induction of RAR␣ mRNA by 80% (Fig. 8) . Short term treatment of cells with phorbol dibutyrate did not change the amount of RAR␤ mRNA induced by retinoic acid. DISCUSSION We have previously found that treatment of B16 mouse melanoma cells with retinoic acid induces a 6-to 8-fold increase in PKC␣ and that this increase appears to be required for growth FIG. 4 . PKC enzyme activity is required for phorbol dibutyrate to increase the amount of His 6 -RAR␣ protein. A, transfected cells were treated with 10 M phorbol dibutyrate alone for 1 h or with 10 M phorbol dibutyrate plus 2.5 M bisindolylmaleimide (PKC enzyme inhibitor) for 1 h. Relative amounts of His 6 -RAR␣ were detected on Western blots using the V5 epitope antibody (the inset is from a representative experiment). The data are expressed as the mean of the relative amount of RAR␣ (normalized for the amount of glyceraldehyde-3-phosphate dehydrogenase) Ϯ S.E. (error bars) from three separate experiments. B, B16 clones KR23 (Lys to Arg mutation at amino acid 368 within the ATP-binding domain) and RE21 (Arg to Ala at amino acid 22; Ala to Glu at amino acid 25 within the pseudosubstrate region; and Lys to Arg mutation at amino acid 368 in the ATP-binding domain) were transfected with the His 6 -RAR␣ plasmid. 24 h post-transfection they were treated with phorbol dibutyrate as indicated. The relative amount of His 6 -RAR␣ was detected by Western blots using the V5 epitope antibody (inset from a representative experiment). The data are expressed as the mean of the relative amount of RAR␣ (normalized for the amount of glyceraldehyde-3-phosphate dehydrogenase) Ϯ S.E. (error bars) from three separate experiments.
TABLE I PKC enzyme activity in wild type and PKC␣ mutant-expressing
B16 clones Cells were lyzed via sonication on ice with 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 1 mM dithiothreitol, 5% Triton X-100, 0.5 mM PMSF, and 10 g/ml aprotinin. The cell lyzate was centrifuged at 12,000 ϫ g for 15 min. The supernatant was loaded onto a DEAE-cellulose anion exchange column (Cellex-D, Bio-Rad), previously equilibrated with column buffer (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.5 mM EGTA, 1 mM dithiothreitol). The column was eluted with several column volumes of column buffer containing 100 mM NaCl. Protein in the eluate was concentrated in a Centricon-30 microconcentrator (Amicon). Protein concentrations were then determine by the Bradford method, and samples were diluted to equal protein amounts prior to assay with the PKC enzyme assay kit from Amersham Biosciences. This system uses synthetic, PKC-specific substrate peptides, which become phosphorylated with the radiolabeled phosphate group from [␥-32 P]ATP. PKC-specific enzyme activity was determined by activity in the absence and presence of a phosphollipid, calcium/phorbol dibutyrate mixture. Radiolabeled peptide was separated from unincorporated [ 32 P]ATP by use of high affinity blotting paper. Enzyme activity was calculated as pmol of 32 P incorporated into the peptide/min/mg of protein. KR 23 is a G418-resistant clone derived from transfection of B16 cells with a plasmid encoding PKC␣ with a mutation in the ATP-binding site. RE 2.1 is a G418-resistant clone derived from transfection of B16 cells with a plasmid encoding PKC␣ with mutation in both the pseudo-substrate region and in the ATP-binding site. 35 S]methionine for 2 h. The cells were then incubated for the indicated times in non-radioactive medium. At each time point, cells were lysed and the radiolabeled His 6 -RAR␣ was immunoprecipitated with antibody to V5 epitope followed by capture of the immune complexes on protein A-agarose beads. The immune complexes were then separated by SDS-PAGE, and the amount of His 6 -RAR␣ was determined by densitometry of the autoradiogram. Cells were treated with 10 M phorbol dibutyrate during the last hour of the pulse period or treated with 10 M phorbol dibutyrate for 24 h prior to the pulse period. The data are plotted as the percentage of the mean radioactive signal from three separate experiments Ϯ S.E. (error bars) for His 6 -RAR␣ measured at the time cells were placed into to non-radioactive medium.
arrest and differentiation (36) . Because PKC has been reported to phosphorylate RAR (29), we decided to investigate the potential interactions between PKC and RAR in our B16 melanoma model system.
Using transient transfection into B16 mouse melanoma cells of a construct containing the gene for 6X-His-RAR␣, we found that the encoded protein has multiple phosphorylated species in agreement with previous published results (37) . However, in contrast to our expectations, activation or down-regulation of the endogenous PKC, through the use of short and long term phorbol dibutyrate treatment, did not change the phosphorylation status of the ectopically expressed RAR␣. This conclusion is based on the observation that manipulation of PKC activity/ expression did not change the ratio of any of the phosphorylated species of RAR␣ nor the amount of 32 P i incorporated into the RAR␣ when the data is corrected for the amount of RAR␣ protein present in the sample. Our finding differs from that of Delmotte et al. (29) , who showed that PKC␣ and ␥ were able to phosphorylate RAR␣ in vitro on a single serine residue (Ser-157). Furthermore, they have shown that this phosphorylation site is at the dimerization interface and thus inhibits formation of RAR⅐RXR heterodimer and transcriptional activity. We have also found that PKC␣ was able to phosphorylate RAR␣ in vitro (data not shown), however our present results suggest that this phosphorylation most likely does not occur in vivo in B16 melanoma cells.
Although activation of PKC did not alter the phosphorylation state of RAR␣, it did increase the amount of this protein. The increase was not due to increased promoter activity of the transfected plasmid, because the same promoter-driving ␤-galactosidase expression did not increase the expression of this transfected gene when the cells were treated for 2 h with phorbol dibutyrate. Although we did not measure RAR␣ mRNA levels with or without addition of phorbol dibutyrate, it is unlikely that changes in RNA level can account for the increase in the amount of RAR␣ protein, because it was detected within 30 min of addition of phorbol dibutyrate to the cells. Indeed, further investigation demonstrated that the increase could be correlated exactly with an increase in the half-life of the RAR␣ protein. It is clear that PKC enzyme activity is required for short term phorbol dibutyrate treatment to increase RAR␣ protein. Both bisindolylmaleimide, a fairly specific inhibitor of PKC, and dominant-negative mutants of PKC␣ that lack enzyme activity, blocked the increase in RAR␣ protein. Although PKC␣ is the major isozyme expressed in B16 cells (31), we are hesitant to claim that this PKC isotope is responsible for the increase in RAR␣, because overexpression of dominant-negative PKC␣ could block maturation of other isozyme by sequestering phosphoinositide-dependent kinase and thus blocking phosphorylation of the activation loop of the PKC enzyme (38) .
Examination of the half-life of RAR␣ in control and treated cells revealed that activation of PKC increased the half-life from 4 to 8 h, whereas down-regulation of PKC decreased the half-life to 3 h. This increase correlates quite well with the increased steady-state level of RAR␣ in phorbol dibutyratetreated cells. Several recent studies have shown that the RARs are degraded through the ubiquitin-proteasome pathway and that binding of ligand by the receptor accelerates its degradation (39 -41) . Because RAR␣ did not appear to be directly phosphorylated by PKC in vivo, we speculate that one of the components of the ubiquitination-ligase system may be negatively regulated by PKC phosphorylation. Alternatively, PKCmediated phosphorylation of associated co-repressors may block ligand-induced conformation change in the RAR␣, leading to stabilization of the protein. However, we consider this mechanism unlikely in light of the increased AF-2 activity in cells having activated PKC (see below).
In two studies PKC has been implicated in stabilizing protein half-life. Lee et al. (42) found that phosphorylation of EGF receptors by PKC decreased their degradation by promoting recycling back to the cell surface. Droms and Malkinson (43) reported that PKC ␤II inhibited the proteasome-dependent proteolysis of FUS nuclear proto-oncogene.
The increased amount of RAR protein in cells having activated PKC probably accounts for the increase in AF-2 activity that we observed. This was found with ectopically expressed RAR␣, ␤, and ␥ as well as with the endogenous RARs. However, the large decrease in AF-2 activity found in PKC down-regulated cells cannot be explained by the change in the receptor half-life from 4 to 3 h. We observed that the loss of PKC resulted in a large decrease in receptor DNA binding. This loss of receptor-DNA binding likely explains the drop in AF-2 activity. One possibility is that down-regulation of PKC affects heterodimer formation of RAR with RXR. It has been reported that RXR⅐RAR heterodimer formation is required for stable DNA binding (14) . RXR is also a phosphoprotein (44) . However, at present, it is not known whether it is phosphorylated by PKC in vivo. Down-regulation of PKC also inhibited induction of RAR␤ mRNA by retinoic acid. This is consistent with a loss of AF-2 activity and DNA binding of RAR in PKC-down-regulated cells.
In summary, in B16 mouse melanoma cells, activation of PKC increases the half-life of RAR␣, which correlates with enhanced AF-2 activity of all of the RAR. Down-regulation of PKC leads to markedly decreased AF-2 activity of the RAR and inhibition of retinoic acid induction of one of its target genes, i.e. RAR␤. Phorbol dibutyrate promotes the formation of skin tumors when chronically applied to mouse skin (45, 46) . We have shown that chronic treatment of B16 mouse melanoma cells with phorbol dibutyrate inhibits the ability of retinoic acid to induce growth arrest and differentiation in these cells (35, 47) . Therefore, we hypothesize that phorbol dibutyrate may accomplish its tumor promoting activity, at least in part, by down-regulating PKC, which in turn blocks the ability of the RAR to transmit the signal of retinoids to regulate growth and/or differentiation.
